PMID- 31474990
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20231213
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Effects of Omalizumab on FcepsilonRI and IgE Expression in Lesional Skin of Bullous 
      Pemphigoid.
PG  - 1919
LID - 10.3389/fimmu.2019.01919 [doi]
LID - 1919
AB  - Recent studies suggest an important role of immunoglobulin E (IgE) as an 
      alternative pathogenic pathway in the development of bullous pemphigoid (BP), as 
      the most frequent subepidermal blistering disease of the skin Use of IgE targeted 
      therapies, such as omalizumab, has been shown promising in recent studies. The 
      aim of this study was to assess the effect of omalizumab on FcepsilonRI and IgE 
      expression on circulating basophils and on lesional intradermal cells in BP to 
      generate insight into the immunological effects of omalizumab in BP. We report 
      two cases of BP patients treated with omalizumab. Efficacy of treatment was 
      assessed clinically 4 months after initiation of the therapy. Lesional and 
      non-lesional skin biopsies where taken before and 4 weeks after initiation of 
      omalizumab therapy. In addition, FcepsilonRI expression on circulating cells and IgE 
      levels in serum and in the skin samples, as well as anti-BP180 and anti-BP230 in 
      serum and eosinophils and basophils counts in blood were assessed before and 
      during treatment. Both patients showed a marked improvement after 4 months, with 
      no adverse effects. Down-regulation of FcepsilonRI, IgE in lesional skin and on 
      circulating basophils were observed in parallel with clinical improvement. The 
      current case study supports the role of omalizumab in the treatment of a subset 
      of BP patients. Our observations suggest that omalizumab represents a valuable 
      therapeutic option in the management of BP patients. Its efficacy might be 
      related to reduction in FcepsilonRI+ and IgE+ basophils and intradermal cells.
FAU - Seyed Jafari, S Morteza
AU  - Seyed Jafari SM
AD  - Department of Dermatology, Inselspital-Bern University Hospital, University of 
      Bern, Bern, Switzerland.
FAU - Gadaldi, Karolina
AU  - Gadaldi K
AD  - Department of Dermatology, Inselspital-Bern University Hospital, University of 
      Bern, Bern, Switzerland.
FAU - Feldmeyer, Laurence
AU  - Feldmeyer L
AD  - Department of Dermatology, Inselspital-Bern University Hospital, University of 
      Bern, Bern, Switzerland.
FAU - Yawalkar, Nikhil
AU  - Yawalkar N
AD  - Department of Dermatology, Inselspital-Bern University Hospital, University of 
      Bern, Bern, Switzerland.
FAU - Borradori, Luca
AU  - Borradori L
AD  - Department of Dermatology, Inselspital-Bern University Hospital, University of 
      Bern, Bern, Switzerland.
FAU - Schlapbach, Christoph
AU  - Schlapbach C
AD  - Department of Dermatology, Inselspital-Bern University Hospital, University of 
      Bern, Bern, Switzerland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190814
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (DST protein, human)
RN  - 0 (Dystonin)
RN  - 0 (Non-Fibrillar Collagens)
RN  - 0 (Receptors, IgE)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Aged
MH  - Anti-Allergic Agents/immunology/therapeutic use
MH  - Autoantibodies/blood/immunology
MH  - Autoantigens/immunology
MH  - Basophils/immunology/metabolism
MH  - Dystonin/immunology
MH  - Eosinophils/immunology/metabolism
MH  - Humans
MH  - Immunoglobulin E/*immunology/metabolism
MH  - Leukocyte Count
MH  - Middle Aged
MH  - Non-Fibrillar Collagens/immunology
MH  - Omalizumab/immunology/*therapeutic use
MH  - Pemphigoid, Bullous/*drug therapy/immunology/metabolism
MH  - Receptors, IgE/*immunology/metabolism
MH  - Skin/*drug effects/immunology/metabolism
MH  - Treatment Outcome
MH  - Collagen Type XVII
PMC - PMC6702353
OTO - NOTNLM
OT  - FcepsilonRI
OT  - IgE
OT  - bullous pemphigoid
OT  - omalizumab
OT  - skin
EDAT- 2019/09/03 06:00
MHDA- 2020/10/06 06:00
PMCR- 2019/01/01
CRDT- 2019/09/03 06:00
PHST- 2019/05/29 00:00 [received]
PHST- 2019/07/29 00:00 [accepted]
PHST- 2019/09/03 06:00 [entrez]
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.01919 [doi]
PST - epublish
SO  - Front Immunol. 2019 Aug 14;10:1919. doi: 10.3389/fimmu.2019.01919. eCollection 
      2019.